Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apnea NEW ORLEANS, June 6, 2026 /PRNewswire/ -- First-ever type 2 diabetes and obesity phase 3 study results for retatrutide, a novel...